InfectRisk

RSV activity in Czechia

Current respiratory syncytial virus (RSV) activity in Czechia, based on ECDC ERVISS weekly data from the State Health Institute (SZÚ).

Influenza: Low

Low

The source currently reports no meaningful activity (as of 16 Aug 2026).

Data window: Week 33 · Aug 10 – Aug 16 · Source: ECDC (weekly) · Source on seasonal break, next data from week 40

Get one free alert when the wave turns in Czechia

We write exactly once: the moment the level goes up. No account, no newsletter. We store your address and the country, nothing else. Every mail has a one click unsubscribe. Privacy

View the last 8 weeks

In week 33 of 2026, Influenza activity in Czechia is classified as low.

The source reports no meaningful activity across these weeks; a week-over-week percentage would be pure noise here.

The last 8 reported weeks

WeekRelativeLevelvs prior week
Week 33Low
Week 32Low
Week 31Low
Week 30Low
Week 29Low
Week 28Low
Week 27Low
Week 26Low

Across these weeks the source reports no meaningful activity, the values sit at the floor of its scale.

Is flu going around right now?

Know when it affects you.

This page shows your country. The app shows you.

  • Exact numbers and incidence rates, not just low, moderate, high
  • Your personal risk by age and region
  • A push alert when the wave tips in your region
  • 35 countries and a home-screen widget
Download on the

Current activity

12-week trend · RSV · Relative development · ECDC ERVISS
Week 22Week 25Week 28Week 30Week 33
  • InfluenzaLow
    Trend: stable · Week 33
  • COVID-19Low
    Trend: stable · Week 33
  • RSVLow
    Trend: stable · Week 33

What this means

In week 33 of 2026, activity of respiratory syncytial virus (RSV) in Czechia is low. The trend, derived from clinical surveillance, is stable.

Data, context and methodology

The current picture for Czechia is built on the European Respiratory Virus Surveillance Summary (ERVISS), published weekly by the European Centre for Disease Prevention and Control (ECDC). the State Health Institute (SZÚ) via the sentinel ARI/ILI network is the national public-health authority that feeds ERVISS with sentinel primary care and virology data.

ECDC ERVISS

ERVISS is ECDC's weekly pan-European surveillance summary for influenza, SARS-CoV-2 and RSV. National authorities, in Czechia's case the State Health Institute (SZÚ) via the sentinel ARI/ILI network, submit harmonised indicators every week, which ECDC publishes in a standardised dataset on Thursdays. Using ERVISS rather than each country's native portal ensures cross-country comparability.

ILI / ARI consultation rates and positivity

the State Health Institute (SZÚ) via the sentinel ARI/ILI network operates a sentinel network of general practices that report weekly rates of patients consulting for influenza-like illness (ILI) or acute respiratory infection (ARI). A subset of patients is swabbed and tested by reference laboratories, producing pathogen-specific positivity rates for flu, SARS-CoV-2 and RSV.

Why this source

Combining consultation incidence with virological positivity yields a pathogen-specific weekly incidence signal (ILI × positivity / 100). This is the standard European methodology and provides a more robust view than either indicator alone: consultation rates capture illness burden, positivity confirms which pathogen is driving it.

Qualitative classification

The “low”, “moderate” and “high” categories follow seasonal reference values and epidemiological thresholds calibrated to match our classifications for other countries. The ILI × positivity / 100 product is scaled to comparable thresholds using a divisor of 3, which aligns European sentinel peaks with the consultation-equivalent scale used elsewhere. Data refreshes weekly when ECDC publishes the latest ERVISS update, typically on Thursdays.

Source and seasonal pattern by pathogen

Influenza
The classification is based on the ECDC ERVISS weekly reports, drawing on data from the State Health Institute (SZÚ) via the sentinel ARI/ILI surveillance network. Seasonally, infection waves in Czechia typically peak between January and March; activity is usually markedly lower during the summer months.
COVID-19
The classification is based on the ECDC ERVISS weekly reports, drawing on COVID-19 surveillance data from the State Health Institute (SZÚ) via the sentinel ARI/ILI surveillance network. Seasonally, infection waves in Czechia typically peak during winter, with occasional summer waves driven by new variants; activity is usually markedly lower in late spring between waves.
RSV
The classification is based on the ECDC ERVISS weekly reports, drawing on RSV surveillance data from the State Health Institute (SZÚ) via the sentinel ARI/ILI surveillance network. Seasonally, infection waves in Czechia typically peak between December and February; activity is usually markedly lower in spring and summer.

Frequently asked questions

When is RSV season in Czechia?

RSV activity in Czechia typically begins rising in late autumn, peaks between December and February, and fades into spring. Post-pandemic seasons have been less predictable than pre-2020 patterns, with earlier or delayed peaks in some years. SZÚ publishes RSV indicators within its weekly respiratory-virus surveillance alongside flu and SARS-CoV-2.

Who is most at risk from RSV in Czechia?

The groups at highest risk of severe RSV are infants (especially those under six months, preterm babies, and infants with underlying heart or lung disease) and older adults, particularly those aged 75 and above or with chronic respiratory or cardiac conditions. In otherwise healthy children and adults, RSV usually resembles a common cold and resolves without complications.

Are RSV vaccines and nirsevimab available in Czechia?

Since 2023, RSV vaccines have been authorised in the EU for older adults and for passive protection of infants. Czechia has progressively adopted the long-acting monoclonal antibody nirsevimab for infants entering their first RSV season, and adult RSV vaccines are recommended for defined risk groups in line with national expert guidance. Uptake and clinical impact are monitored through SZÚ's weekly surveillance.

How is RSV tracked in Czechia?

RSV surveillance in Czechia combines sentinel ARI data, virological testing coordinated by SZÚ, and hospital-admission signals for severe paediatric and adult respiratory infection. Weekly results are published by SZÚ and also reported to ECDC ERVISS, which lets Czechia's RSV curve be compared directly with neighbours such as Germany, Austria, and Poland.

How does RSV differ from flu in Czech data?

In SZÚ surveillance, flu and RSV appear as separate positivity streams within the same respiratory panel. RSV disproportionately affects infants and the very elderly, while flu burden spreads across age bands and is especially severe in older adults. Symptom overlap between the two viruses is wide, so the distinction relies on laboratory testing rather than clinical impression.

More situation reports

ECDC ERVISSECDC DataUpdated: Aug 31, 2026, 11:11
Published by Dominik Martin · Software engineer and data aggregator· Methodology last reviewed: 07 May 2026· Methodology version 1.2

Data last refreshed: Aug 31, 2026, 11:11. Update cadence: weekly.

This page is not medical advice and does not replace consultation with a healthcare professional. For specific symptoms, please contact a medical professional.

About this page

Published by Renderei Martin GmbH, Berlin. No commercial interest in individual health recommendations. The app is optionally monetised via a freemium subscription.

Content is based exclusively on the linked official surveillance publications. Medical statements are curated against the guidance of RKI, ECDC and WHO.

Methodology enquiries: press@infectrisk.com

About this site and its author